IDO1-IN-34
IDO1-IN-34 is a selective IDO1 inhibitor with an IC50 of 0.093 μM. IDO1-IN-34 exhibits cytotoxicity against various cancer cell lines. IDO1-IN-34 inhibits the kynurenine (kynurenine) pathway and activates IL-2. IDO1-IN-34 induces cell apoptosis via the endogenous mitochondrial pathway, while increasing the levels of cytochrome c, caspase-3, caspase-9 and PARP-1. IDO1-IN-34 can be used for research on liver cancer, lung cancer, breast cancer, prostate cancer, colon cancer and leukemia.
For research use only. We do not sell to patients.
- Formula: C18H10BrF7N4O2
- Molecular Weight:527.19
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
IDO1 0.093 μM (IC50) |
IL-2 |
Caspase-9 |
Caspase-3 |
PARP-1 |
In Vitro
IDO1-IN-34 (Compound 3b) (0.1-100 μM; 48 h) exhibits selective cytotoxicity against a variety of cancer cell lines, with the highest potency against HepG2 cells (GI50 = 0.72 μM). It shows extremely low cytotoxicity against non-cancerous Vero cells, resulting in a selectivity index of 121.58 for HepG2 cells[1].
IDO1-IN-34 (0.03-0.3 μM; 24 h) dose-dependently reduces kynurenine production in IFN-γ-stimulated SK-OV-3 cells and reverses IDO1-mediated immunosuppression[1].
IDO1-IN-34 (0.03-0.3 μM; 2 days) restores T cell activation in a dose-dependent manner and increases IL-2 expression in an IDO1-inhibited SK-OV-3/Jurkat T cell co-culture system[1].
IDO1-IN-34 (0.36-0.72 μM; 24 h) induces apoptosis in HepG2 cells in a dose-dependent manner[1].
IDO1-IN-34 (0.36-0.72 μM; 48 h) dose-dependently activates the endogenous mitochondrial apoptotic pathway in HepG2 cells, as evidenced by increased levels of cleaved caspase-3, cleaved caspase-9, cleaved PARP-1, and cytochrome c, without activating cleaved caspase-8, a marker of the exogenous apoptotic pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2, A549, MCF-7, PC-3, HT-29, K562, Vero
-
Concentration:0.1-100 μM
-
Incubation Time:48 h
-
Result:Exhibited a GI50 of 0.72 μM against HepG2 liver cancer cells.
Exhibited a GI50 of 3.02 μM against A549 lung cancer cells.
Exhibited a GI50 of 4.55 μM against MCF-7 breast cancer cells.
Exhibited a GI50 of 3.28 μM against PC-3 prostate cancer cells.
Exhibited a GI50 of 6.04 μM against HT-29 colon cancer cells.
Exhibited a GI50 of 10.27 μM against K562 leukemia cells.
Exhibited a GI50 of 87.54 μM against non-cancerous Vero cells.
Yielded selectivity indices of 121.58 (HepG2), 28.98 (A549), 19.23 (MCF-7), 26.68 (PC-3), 14.49 (HT-29), and 8.52 (K562).
-
Cell Line:SK-OV-3/Jurkat T-cell co-cultures
-
Concentration:0.03, 0.1, 0.3 μM
-
Incubation Time:2 days
-
Result:Increased IL-2 levels to 416.59 pg/mL at 0.03 μM compared to 161.03 pg/mL in IFN-γ-only treated co-cultures.
Increased IL-2 levels to 648.84 pg/mL at 0.1 μM compared to 161.03 pg/mL in IFN-γ-only treated co-cultures.
Increased IL-2 levels to 865.67 pg/mL at 0.3 μM compared to 161.03 pg/mL in IFN-γ-only treated co-cultures.
-
Cell Line:HepG2 liver cancer cells
-
Concentration:0.36 μM, 0.72 μM
-
Incubation Time:24 h
-
Result:Increased total apoptosis (early + late) to 36.16% at 0.36 μM compared to 9.13% in control cells.
Increased total apoptosis (early + late) to 59.33% at 0.72 μM compared to 9.13% in control cells.
-
Cell Line:HepG2 liver cancer cells
-
Concentration:0.36 μM, 0.72 μM
-
Incubation Time:48 h
-
Result:Dose-dependently increased levels of cytochrome c, cleaved caspase-3, cleaved caspase-9, and cleaved PARP-1.
Dose-dependently reduced levels of total caspase-3, total caspase-9, and total PARP-1.
Did not increase cleaved caspase-8 levels at either concentration tested.
Chemical Information
-
Molecular Weight 527.19
-
Formula C18H10BrF7N4O2
-
SMILES
O=C(C1=NNN=C1C2=CC(C(F)(F)F)=CC(Br)=C2)NC3=CC=C(C(OCC(F)(F)F)=C3)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)